Slough, UK, 20 November 2018 – Indivior PLC (LON: INDV) “Indivior is disappointed that the U.S. Court of Appeals for the Federal Circuit has vacated the preliminary injunction against Dr. Reddy’s Laboratories (“DRL”). Indivior will continue to vigorously pursue ongoing infringement cases against DRL to protect its SUBOXONE® (buprenorphine and naloxone) Sublingual Film patent portfolio. The Company is in the process of interpreting the ruling in its entirety and will issue a statement on its implications once this review has been completed.”
For Further Information
Investor Enquiries
Jason Thompson
VP Investor Relations, Indivior PLC
+1 804 379 1033
jason.thompson@indivior.com
Media Enquiries
Jonathan Sibun
Tulchan Communications US Media Enquiries
+44 207 353 4200 +1 804 594 0836
Indiviormediacontacts@indivior.com
Share